Mapping of the 45M1 epitope to the C-terminal cysteine-rich part of the human MUC5AC mucin.

Department of Medical Biochemistry, Göteborg University, Sweden.
FEBS Journal (Impact Factor: 3.99). 03/2008; 275(3):481-9. DOI: 10.1111/j.1742-4658.2007.06215.x
Source: PubMed

ABSTRACT Mucins are large glycoproteins protecting mucosal surfaces throughout the body. Their expressions are tissue-specific, but in disease states such as cystic fibrosis, inflammation and cancer, this specificity can be disturbed. MUC5AC is normally expressed in the mucous cells of the epithelia lining the stomach and the trachea, where it constitutes a major component of the gastric and respiratory mucus. A number of mAbs have been raised against the gastric M1 antigen, an early marker for colonic carcinogenesis. Several of these mAbs recognize epitopes present on MUC5AC, suggesting that MUC5AC is the antigen. However, some of the mAbs raised against the gastric M1 antigen are widely used as antibodies against MUC5AC, despite the fact that their specificity for MUC5AC has not been clearly shown. In this study, we have tested the reactivity of the latter antibodies against a recombinantly expressed C-terminal cysteine-rich part of human MUC5AC. We demonstrate for the first time that the widely used mAb 45M1, as well as 2-12M1 and 166M1, are true antibodies against MUC5AC, with epitopes located in the C-terminal cysteine-rich part of the mucin.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Mucins are related to infectious and non-infectious diseases in Veterinary and Human Medicine. MUC1 mucin is a transmembrane glycoprotein expressed on the apical surface of human epithelia while MUC5AC is the predominant secreted mucin expressed in human gastric epithelium and goblet cells of lung and eyes. MUC5AC C-terminus cysteine rich regions and the cytoplasmic tail of MUC1 domains are conserved among several mammalian species. Objective: to compare the expression of MUC1 and MUC5AC mucins in mammalian epithelia. CT33 anti-MUC1 cytoplasmic tail (MUC1CT) polyclonal antibody and 45M1 anti-MUC5AC monoclonal antibody were employed. By immunohistochemistry, MUC1CT was expressed in most tissues while MUC5AC was restricted to gastric surface epithelium and goblet cells from trachea and lung. By western blot, MUC1CT showed a band at approximately 35 kDa in most tissues; MUC5AC revealed bands at >180 kDa in stomach and lung secretions from rat, cat, pig and cow. When rat MUC5AC was immunoprecipitated, a band at about 180 kDa was obtained.
    Research in Veterinary Science 06/2008; 86(1):68-77. DOI:10.1016/j.rvsc.2008.05.011 · 1.51 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Nasal polyps are believed that they may be caused by allergy and cystic fibrosis. Despite elimination by surgery, nasal polyps are observed to recur about 70%. Most importantly, the pathogenesis of nasal polyps has been unknown. Therefore, the molecular mechanisms that increase mucous hypersecretion in nasal polyps should be identified. The understanding of these mechanisms is important for developing new therapeutic strategies. The aim of this study was to identify the effect of the regulator of G protein signaling 4 protein (RGS4) on nasal polyps and to investigate the role of the ATP-sensitive potassium (KATP) channel on lipopolysaccharide (LPS)-induced mucin-5AC protein (MUC5AC) expression in vivo. MUC5AC and RGS4 expressions were studied by immunoblotting in human nasal polyp and in lungs from Rgs4 knock-out mice. Glybenclamide and apyrase were challenged i.p. injection for 2 hr in prior to LPS instillation using tracheostomy. We found that the expression of RGS4 was dramatically suppressed to about 70% in the polyp specimens compared to that in the normal nasal mucosa. This finding suggests that defective RGS4 expression may have a role in the increased MUC5AC expression in the epithelia of human nasal polyps. Inhibition of the KATP channel leads to diminished MUC5AC overexpression in vivo. Since the KATP channel can be mediated in LPS-induced MUC5AC expression in vivo, the KATP channel may be a good target for regulating mucous hypersecretion in respiratory diseases.
    Fetal ovine model for in-situ esophagus tissue engineering 02/2013; 10(1). DOI:10.1007/s13770-013-0372-x · 0.61 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Helicobacter pylori attaches to mucin oligosaccharides that are expressed on host gastric epithelium. We used the rhesus macaque model to characterize the effect of H. pylori infection on gastric mucin oligosaccharides during acute and chronic infection. Specific pathogen (H. pylori)-free rhesus macaques were inoculated with H. pylori J166. Biopsy specimens of the gastric antrum were obtained 2 and 4 weeks before and 2, 8, and 24 weeks after infection with H. pylori. O-linked mucin oligosaccharides were released from gastric biopsy samples by beta-elimination and profiled by matrix-assisted laser desorption/ionization mass spectrometry. Similar studies were performed on gastric biopsy samples from H. pylori-infected and uninfected humans. Formalin-fixed, paraffin-embedded sections of rhesus antrum biopsy samples were stained with H&E, periodic acid-Schiff stain, and antibody to MUC5AC, the predominant mucin expressed in the stomach. H. pylori-induced gastritis was accompanied by an acute and dramatic decrease in diversity and relative abundance of O-linked mucin oligosaccharides in the rhesus stomach, which largely recovered during the 24-week observation period. These variations in oligosaccharide abundance detected by mass spectrometry were reflected by changes in periodic acid-Schiff-positive material and expression of MUC5AC over time. Relatively few differences were seen in gastric mucin oligosaccharide composition between H. pylori-infected and uninfected patients, which is consistent with the results in rhesus macaques because infection occurs in childhood. Acute H. pylori infection is accompanied by a dramatic but transient loss in mucin oligosaccharides that may promote colonization and persistence.
    Gastroenterology 05/2009; 137(3):1061-71, 1071.e1-8. DOI:10.1053/j.gastro.2009.04.014 · 13.93 Impact Factor